Ftse Mib
35.854,07
-0,57%
DAX
21.254,27
1,01%
S&P 500
6.086,37
0,61%
NASDAQ
20.009,34
1,28%
Bitcoin
102.875,01
-0,73%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Tyra Biosciences Inc (TYRA) Tyra Biosciences Inc (TYRA) Notizie

Tyra Biosciences Inc

TYRA
15,80
-0,11 (-0,69%)
23 Gen 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
23/1/202500:00EDGAR2Form 144 - Report of proposed sale of securities
22/1/202514:00PRNUSTyra Biosciences Announces Poster Presentations at 2025 ASCO..
10/1/202514:00PRNUSTyra Biosciences Receives IND Clearance from FDA to Proceed..
09/12/202423:42EDGAR2Form 144 - Report of proposed sale of securities
07/12/202403:30EDGAR2Form SC 13D/A - General Statement of Acquisition of..
05/12/202422:21EDGAR2Form 144 - Report of proposed sale of securities
03/12/202401:06EDGAR2Form 144 - Report of proposed sale of securities
20/11/202422:29EDGAR2Form 144 - Report of proposed sale of securities
20/11/202403:31EDGAR2Form SC 13D/A - General Statement of Acquisition of..
14/11/202423:52EDGAR2Form 144 - Report of proposed sale of securities
13/11/202422:05PRNUSTyra Biosciences to Present at Upcoming Investor Conferences
07/11/202422:05EDGAR2Form 8-K - Current report
07/11/202422:05PRNUSTyra Biosciences Reports Third Quarter 2024 Financial..
30/10/202421:01EDGAR2Form 144 - Report of proposed sale of securities
28/10/202422:15EDGAR2Form 144 - Report of proposed sale of securities
28/10/202412:00EDGAR2Form 8-K - Current report
28/10/202412:00PRNUSTyra Biosciences Receives IND Clearance from FDA to Proceed..
25/10/202414:01EDGAR2Form 8-K - Current report
25/10/202400:21PRNUSTyra Biosciences Reports Interim Clinical Proof-of-Concept..
23/10/202422:05PRNUSTyra Biosciences to Host Conference Call on Interim Clinical..
23/10/202403:15EDGAR2Form SC 13D/A - General Statement of Acquisition of..
23/10/202402:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/10/202402:47EDGAR2Form 3 - Initial statement of beneficial ownership of..
18/10/202422:23EDGAR2Form 8-K - Current report
11/10/202414:00PRNUSTyra Biosciences Announces Late-Breaking Oral Presentation..
18/9/202422:05EDGAR2Form 144 - Report of proposed sale of securities
18/9/202421:27EDGAR2Form 144 - Report of proposed sale of securities
11/9/202422:05PRNUSTyra Biosciences to Present at the 2024 Cantor Global..
10/9/202422:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/9/202422:49EDGAR2Form 3 - Initial statement of beneficial ownership of..
10/9/202422:05PRNUSTyra Biosciences Appoints Doug Warner, M.D., as Chief..
16/8/202423:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/8/202422:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202422:05EDGAR2Form 8-K - Current report
07/8/202422:05PRNUSTyra Biosciences Reports Second Quarter 2024 Financial..
02/7/202422:05PRNUSTyra Biosciences Announces Preclinical Proof-of-Concept..
11/6/202401:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/6/202421:08EDGAR2Form 144 - Report of proposed sale of securities
31/5/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/5/202422:02EDGAR2Form 8-K - Current report
23/5/202422:05PRNUSTyra Biosciences to Present at Upcoming Investor Conferences
09/5/202422:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/5/202422:46EDGAR2Form 3 - Initial statement of beneficial ownership of..
09/5/202422:12EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/5/202422:08EDGAR2Form 8-K - Current report
09/5/202422:05PRNUSTyra Biosciences Reports First Quarter 2024 Financial..
07/5/202422:34EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
07/5/202422:29EDGAR2Form 8-K - Current report
07/5/202422:05PRNUSTyra Biosciences Announces Appointments of Susan Moran,..
19/3/202421:05PRNUSTyra Biosciences Reports Fourth Quarter and Full Year 2023..
Apertura: 15,70 Min: 15,24 Max: 16,045
Chiusura: 15,91

La tua Cronologia

NASDAQ
TYRA
Tyra Biosciences
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network